Product
Why ELNs and LIMS are not enough for PD teamsOne of the questions we’re asked frequently is whether Invert is an ELN or LIMS—our answer is that Invert captures both systems’ strengths and fixes their weaknesses. We’ll discuss the trade-offs and shortcomings of ELN and LIMS when it comes to bioprocess data to explain how.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
A Guide to Build vs Buy: Biotech Software Edition
For biotech and synthetic biology companies, there’s always A LOT of work to do. As these companies quickly learn, trying to handle everything in-house–from strain design and high-throughput screening to process development and beyond–can spread funding and resources thinly.
Pioneers in Bioprocessing: Q&A with Biopharma Executive, Steven Lang, Ph.D.
Biotech and synthetic biology companies have much to do. Handling everything in-house—from strain design to process development—can stretch funding and resources thin.
.png)